Cassava Sciences shares drop as Alzheimer's drug fails in late-stage study

Filana Therapeutics

25/11/2024 13:42

** Shares of drug developer Cassava Sciences  SAVA.O  down
85.42% premarket to $3.86, its experimental Alzheimer's disease
drug, simufilam, did not meet the main or secondary goals in a
late-stage study.
    ** As a result, Cassava will discontinue a second late-stage
study, as well as its open-label study of the drug
    ** Cassava's shares were halted in premarket hours ahead of
the announcement
    ** Up to the previous session's close, shares were up 17.6%​
YTD
    
  

 (Repoting by Joao Manuel Mauricio)